Sharon Waymer

FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia.

Thomas S. Lin, J. Byrd, I. Flinn, 2005, Blood.

Antibody therapy for chronic lymphocytic leukemia: a promising new modality.

M. Grever, J. Byrd, D. Fischer, 2004, Hematology/oncology clinics of North America.

to alemtuzumab in chronic lymphocytic leukemia FCGR3A and FCGR2A polymorphisms may not correlate with response

J. Byrd, I. Flinn, R. Modali, 2013 .

Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma

Jeffrey A Jones, J. Byrd, F. Awan, 2015, Leukemia & lymphoma.

A Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL)

Jeffrey A Jones, J. Byrd, F. Awan, 2015 .

Updated Results from a Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL) and Richter's Transformation or Ibrutinib for Patients with Ibrutinib-Resistant Clones

Jeffrey A Jones, J. Byrd, F. Awan, 2016 .